Moderna’s R&D Day Indicates Covid-19 Will Remain The Biggest Driver Of The Stock

Sept. 14, 2021, 7:30 a.m.

(Forbes) The success of the company’s Covid-19 vaccine helps to validate the safety and efficacy of Moderna’s mRNA technology, to an extent, and likely reduces the risk surrounding the rest of Moderna’s sizable pipeline which has developments ranging from vaccines for infectious diseases to drugs targetin...

Login to grade this article.